Sections

Medication

Medication Summary

In August 2021, the FDA approved, calcium/magnesium/potassium/sodium oxybates (Xywav), the first drug indicated for idiopathic hypersomnia. It is a CNS depressant that contains salts of gamma hydroxybutyrate, an endogenous compound and metabolite of the neurotransmitter GABA. It may be administered as either a once or twice nightly regimen.

Daytime stimulants

Patients often require drug therapy to treat daytime hypersomnolence. Prior to initiating therapy with stimulants, clearly establish a diagnosis and consider potential for abuse.^{[83, 75]}

Modafinil, a wake-promoting agent, is approved for treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea-hypopnea syndrome (OSAHS), and shift-work sleep disorder (SWSD).^{[88, 84]}The studies have shown significant benefits on various objective measures and subjective estimates of excessive sleepiness.

The clinical efficacy of modafinil, combined with its improved safety over CNS stimulants, has made it the most prescribed medication for the treatment of excessive sleepiness associated with narcolepsy. Unlike many other medications used for excessive sleepiness, modafinil is not known to be abused. The most common adverse event reported in clinical studies was headaches; most were transient and mild to moderate in severity. Modafinil also has the potential for interactions with other drugs metabolized via cytochrome P450 enzyme pathways.

For Kleine-Levin syndrome, somnolence can decrease with stimulants (mainly amphetamines), while neuroleptics and antidepressants are of poor benefit. Lithium, rather than carbamazepine or other antiepileptics, was found to have a higher success rate for stopping relapses.^[89]

Class Summary

Mixture of calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate (gamma-hydroxybutyrate [GHB]). GHB is an endogenous compound and metabolite of the neurotransmitter GABA.

Calcium/magnesium/potassium/sodium oxybates (Xywav)

View full drug information

Indicated for adults with idiopathic hypersomnia.

Class Summary

These agents have wake-promoting activities.

Modafinil (Provigil)

View full drug information

Modafinil, (1:1 racemic mixture of R- and S-modafinil) improves wakefulness, though the mechanism of action remains unclear. It may act at the dopamine receptor (DAT), inhibiting dopamine reuptake and may exert stimulant effects by decreasing GABA-medicated neurotransmission. It has wake-promoting actions similar to those of sympathomimetic agents, though no direct action on dopamine receptors themselves; wakefulness is not attenuated by known dopamine antagonists.

Armodafinil (Nuvigil)

View full drug information

Armodafinil is an R-enantiomer of modafinil (mixture of R- and S-enantiomers). It elicits wake-promoting actions similar to those of sympathomimetic agents, although its pharmacologic profile is not identical to sympathomimetic amines and has no direct action on dopamine receptors themselves. Wakefulness is not attenuated by known dopamine antagonists. It may act at the dopamine receptor (DAT), inhibiting dopamine reuptake and may exert stimulant effects by decreasing GABA-medicated neurotransmission. It is not a direct- or indirect-acting dopamine receptor agonist. Armodafinil is indicated for the improvement of wakefulness in individuals with excessive sleepiness associated with narcolepsy, obstructive sleep apnea-hypopnea syndrome (OSAHS), or shift-work sleep disorder.

Methylphenidate (Ritalin, Daytrana, Methylin, Concerta)

View full drug information

Methylphenidate is used for symptomatic management of primary hypersomnolence whenever the patient needs to be alert or engages in activities in which hypersomnolence may be hazardous. The drug blocks the reuptake mechanism of dopaminergic neurons. Methylphenidate stimulates the cerebral cortex and subcortical structures.

Dextroamphetamine (Procentra, Dexedrine, Zenzedi)

View full drug information

This agent increases the amount of circulating dopamine and norepinephrine in the cerebral cortex by blocking the reuptake of norepinephrine or dopamine from the synapse.

Dextroamphetamine and amphetamine mixtures (Mydayis, Adderall XR)

View full drug information

This agent produces CNS and respiratory stimulation. The CNS effect may occur in the cerebral cortex and reticular activating system. Dextroamphetamine-amphetamine mixture may have a direct effect on alpha- and beta-receptor sites in the peripheral system and may also release stores of norepinephrine in adrenergic nerve terminals. The mixture contains various salts of amphetamine and dextroamphetamine. It is available as 5-, 7.5-, 10-, 12.5-, 15-, 20-, and 30mg scored tablets.

Amphetamine (Evekeo)

View full drug information

Amphetamines are noncatecholamine sympathomimetic amines that promote release of catecholamines from their storage sites in the presynaptic nerve terminals. Amphetamine 1:1 racemic mixture of dextroamphetamine and levoamphetamine (immediate release only) has an FDA indication for promoting wakefulness in narcolepsy.

Questions

Roehrs T, Zorick F, Sicklesteel J. Excessive daytime sleepiness associated with insufficient sleep. Sleep. 1983. 6(4):319-25. [QxMD MEDLINE Link].
Billiard M. Diagnosis of narcolepsy and idiopathic hypersomnia. An update based on the International classification of sleep disorders, 2nd edition. Sleep Med Rev. 2007 Oct. 11(5):377-88. [QxMD MEDLINE Link].
Guilleminault C. Disorders of excessive sleepiness. Ann Clin Res. 1985. 17(5):209-19. [QxMD MEDLINE Link].
Arnulf I, Lin L, Gadoth N, File J, Lecendreux M, Franco P, et al. Kleine-Levin syndrome: a systematic study of 108 patients. Ann Neurol. 2008 Apr. 63 (4):482-93. [QxMD MEDLINE Link].
Lavault S, Golmard JL, Groos E, Brion A, Dauvilliers Y, Lecendreux M, et al. Kleine-Levin syndrome in 120 patients: differential diagnosis and long episodes. Ann Neurol. 2015 Mar. 77 (3):529-40. [QxMD MEDLINE Link].
Abe K. Lithium prophylaxis of periodic hypersomnia. Br J Psychiatry. 1977 Mar. 130:312-3. [QxMD MEDLINE Link].
Itokawa K, Fukui M, Ninomiya M, Yamamoto T, Imabayashi E, Tamura N, et al. Gabapentin for Kleine-Levin syndrome. Intern Med. 2009. 48 (13):1183-5. [QxMD MEDLINE Link].
Peraita-Adrados R, Vicario JL, Tafti M, García de León M, Billiard M. Monozygotic twins affected with Kleine-Levin syndrome. Sleep. 2012 May 1. 35 (5):595-6. [QxMD MEDLINE Link].
Ueno T, Fukuhara A, Ikegami A, Ohishi F, Kume K. Monozygotic twins concordant for Kleine-Levin syndrome. BMC Neurol. 2012 May 30. 12:31. [QxMD MEDLINE Link].
Roth B. Narcolepsy and hypersomnia: review and classification of 642 personally observed cases. Schweiz Arch Neurol Neurochir Psychiatr. 1976. 119(1):31-41. [QxMD MEDLINE Link].
Arnulf I, Zeitzer JM, File J, et al. Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain. 2005 Dec. 128(Pt 12):2763-76. [QxMD MEDLINE Link].
Arnulf I, Rico TJ, Mignot E. Diagnosis, disease course, and management of patients with Kleine-Levin syndrome. Lancet Neurol. 2012 Oct. 11 (10):918-28. [QxMD MEDLINE Link].
Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep Medicine. 6th edition. Philadelphia, PA: Elsevier; 2017.
Arnulf I, Lin L, Gadoth N, File J, Lecendreux M, Franco P, et al. Kleine-Levin syndrome: a systematic study of 108 patients. Ann Neurol. 2008 Apr. 63 (4):482-93. [QxMD MEDLINE Link].
Salter MS, White PD. A variant of the Kleine-Levin syndrome precipitated by both Epstein-Barr and varicella-zoster virus infections. Biol Psychiatry. 1993 Mar 1. 33 (5):388-90. [QxMD MEDLINE Link].
GALLINEK A. The Kleine-Levin syndrome: hypersomnia, bulimia, and abnormal mental states. World Neurol. 1962 Mar. 3:235-43. [QxMD MEDLINE Link].
American Academy of Sleep Medicine. International Classification of Sleep Disorders. Third Edition (ICSD-3). Westchester, IL: American Academy of Sleep Medicine; 2014.
Kas A, Lavault S, Habert MO, Arnulf I. Feeling unreal: a functional imaging study in patients with Kleine-Levin syndrome. Brain. 2014 Jul. 137 (Pt 7):2077-87. [QxMD MEDLINE Link].
A Brierre de Boismont. Des Hallucinations: Ou Histoire Raisonnée des Apparitions, des Visions, des Songes, de l'Extase, des Rêves, du Magnetisme Et du Somnambulisme. Paris: Germer Baillière; 1862.
Billiard M, Jaussent I, Dauvilliers Y, Besset A. Recurrent hypersomnia: a review of 339 cases. Sleep Med Rev. 2011 Aug. 15 (4):247-57. [QxMD MEDLINE Link].
Gadoth N, Kesler A, Vainstein G, Peled R, Lavie P. Clinical and polysomnographic characteristics of 34 patients with Kleine-Levin syndrome. J Sleep Res. 2001 Dec. 10 (4):337-41. [QxMD MEDLINE Link].
Huang YS, Guilleminault C, Lin KL, Hwang FM, Liu FY, Kung YP. Relationship between Kleine-Levin syndrome and upper respiratory infection in Taiwan. Sleep. 2012 Jan 1. 35 (1):123-9. [QxMD MEDLINE Link].
Arnulf I, Zeitzer JM, File J, Farber N, Mignot E. Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain. 2005 Dec. 128 (Pt 12):2763-76. [QxMD MEDLINE Link].
GALLINEK A. The Kleine-Levin syndrome: hypersomnia, bulimia, and abnormal mental states. World Neurol. 1962 Mar. 3:235-43. [QxMD MEDLINE Link].
Shukla GD, Bajpai HS, Mishra DN. Kleine-levin syndrome: a case report from India. Br J Psychiatry. 1982 Jul. 141:97-8. [QxMD MEDLINE Link].
Landtblom AM, Dige N, Schwerdt K, Säfström P, Granérus G. Short-term memory dysfunction in Kleine-Levin syndrome. Acta Neurol Scand. 2003 Nov. 108 (5):363-7. [QxMD MEDLINE Link].
CRITCHLEY M. Periodic hypersomnia and megaphagia in adolescent males. Brain. 1962 Dec. 85:627-56. [QxMD MEDLINE Link].
American Sleep Disorders Association. The international classification of sleep disorders: Diagnosis and coding manual. Chicago, IL: American Academy of Sleep Medicine; 1990.
American Academy of Sleep Medicine. The international classification of sleep disorders—revised. Chicago, IL: American Academy of Sleep Medicine; 2005.
Rosenow F, Kotagal P, Cohen BH, Green C, Wyllie E. Multiple sleep latency test and polysomnography in diagnosing Kleine-Levin syndrome and periodic hypersomnia. J Clin Neurophysiol. 2000 Sep. 17 (5):519-22. [QxMD MEDLINE Link].
Katz JD, Ropper AH. Familial Kleine-Levin syndrome: two siblings with unusually long hypersomnic spells. Arch Neurol. 2002 Dec. 59 (12):1959-61. [QxMD MEDLINE Link].
Portilla P, Durand E, Chalvon A, Habert M, Navelet Y, Prigent A, et al. [SPECT-identified hypoperfusion of the left temporomesial structures in a Kleine-Levin syndrome]. Rev Neurol (Paris). 2002 May. 158 (5 Pt 1):593-5. [QxMD MEDLINE Link].
Arnulf I, Lecendreux M, Franco P, Dauvilliers Y. [Kleine-Levin syndrome: state of the art]. Rev Neurol (Paris). 2008 Aug-Sep. 164 (8-9):658-68. [QxMD MEDLINE Link].
Schenck CH, Arnulf I, Mahowald MW. Sleep and sex: what can go wrong? A review of the literature on sleep related disorders and abnormal sexual behaviors and experiences. Sleep. 2007 Jun. 30 (6):683-702. [QxMD MEDLINE Link].
Malhotra S, Das MK, Gupta N, Muralidharan R. A clinical study of Kleine-Levin syndrome with evidence for hypothalamic-pituitary axis dysfunction. Biol Psychiatry. 1997 Aug 15. 42 (4):299-301. [QxMD MEDLINE Link].
VLACH V. [Periodic somnolence, bulimia and mental disorder (Kleine-Levin syndrome)]. Cesk Neurol. 1962 Nov. 25:401-5. [QxMD MEDLINE Link].
Domzał-Stryga A, Emeryk-Szajewska B, Kowalski J. [A case of hypersomnia resembling Kleine-Levin syndrome]. Neurol Neurochir Pol. 1986 Mar-Apr. 20 (2):158-60. [QxMD MEDLINE Link].
Manni R, Martinetti M, Ratti MT, Tartara A. Electrophysiological and immunogenetic findings in recurrent monosymptomatic-type hypersomnia: a study of two unrelated Italian cases. Acta Neurol Scand. 1993 Oct. 88 (4):293-5. [QxMD MEDLINE Link].
Hegarty A, Merriam AE. Autonomic events in Kleine-Levin syndrome. Am J Psychiatry. 1990 Jul. 147 (7):951-2. [QxMD MEDLINE Link].
Koerber RK, Torkelson R, Haven G, Donaldson J, Cohen SM, Case M. Increased cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in Kleine-Levin syndrome. Neurology. 1984 Dec. 34 (12):1597-600. [QxMD MEDLINE Link].
Fukunishi I, Hosokawa K. A female case with the Kleine-Levin syndrome and its physiopathologic aspects. Jpn J Psychiatry Neurol. 1989 Mar. 43 (1):45-9. [QxMD MEDLINE Link].
Kleine W. Periodische schlafsucht. Monatsschr Psychiatr Neurol. 1925. 285-320.
Smolík P, Roth B. Kleine-Levin syndrome ethiopathogenesis and treatment. Acta Univ Carol Med Monogr. 1988. 128:5-94. [QxMD MEDLINE Link].
Billiard M, Guilleminault C, Dement WC. A menstruation-linked periodic hypersomnia. Kleine-Levin syndrome or new clinical entity?. Neurology. 1975 May. 25 (5):436-43. [QxMD MEDLINE Link].
Rocamora R, Gil-Nagel A, Franch O, Vela-Bueno A. Familial recurrent hypersomnia: two siblings with Kleine-Levin syndrome and menstrual-related hypersomnia. J Child Neurol. 2010 Nov. 25 (11):1408-10. [QxMD MEDLINE Link].
Sachs C, Persson HE, Hagenfeldt K. Menstruation-related periodic hypersomnia: a case study with successful treatment. Neurology. 1982 Dec. 32 (12):1376-9. [QxMD MEDLINE Link].
Billiard M, Guilleminault C, Dement WC. A menstruation-linked periodic hypersomnia: Kleine-Levin syndrome or new clinical entity?. Neurology. 1975. 25:436-443. [QxMD MEDLINE Link].
American Academy of Sleep Medicine. International classification of Sleep Disorders. 3rd edition. Darien, IL: American Academy of Sleep Medicine.;
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth edition. Arlington, VA: American Psychiatric Association; 2013.
Rye DB, Bliwise DL, Parker K, Trotti LM, Saini P, Fairley J, et al. Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors. Sci Transl Med. 2012 Nov 21. 4 (161):161ra151. [QxMD MEDLINE Link].
Montplaisir J, Poirier G. HLA in disorders of excessive sleepiness without cataplexy in Canada. Honda Y, Juti T. HLA in Narcolepsy. Berlin, Germany: Springer-Verlag; 1988. 186-190.
Bassetti C, Aldrich MS. Idiopathic hypersomnia. A series of 42 patients. Brain. 1997 Aug. 120 ( Pt 8):1423-35. [QxMD MEDLINE Link].
Poirier G, Montplaisir J, Décary F, Momège D, Lebrun A. HLA antigens in narcolepsy and idiopathic central nervous system hypersomnolence. Sleep. 1986. 9 (1 Pt 2):153-8. [QxMD MEDLINE Link].
Billiard M. Idiopathic hypersomnia. Neurol Clin. 1996 Aug. 14 (3):573-82. [QxMD MEDLINE Link].
Honda Y, Honda M. [Idiopathic hypersomnia--review of literatures and clinical experiences on 16 Japanese cases]. Nihon Rinsho. 1998 Feb. 56 (2):371-5. [QxMD MEDLINE Link].
Lippert J, Halfter H, Heidbreder A, Röhr D, Gess B, Boentert M, et al. Altered dynamics in the circadian oscillation of clock genes in dermal fibroblasts of patients suffering from idiopathic hypersomnia. PLoS One. 2014. 9 (1):e85255. [QxMD MEDLINE Link].
Guilleminault C, Faull KF, Miles L. Posttraumatic excessive daytime sleepiness: a review of 20 patients. Neurology. 1983 Dec. 33(12):1584-9. [QxMD MEDLINE Link].
Montplaisir J, de Champlain J, Young SN. Narcolepsy and idiopathic hypersomnia: biogenic amines and related compounds in CSF. Neurology. 1982 Nov. 32(11):1299-302. [QxMD MEDLINE Link].
Montplaisir J, de Champlain J, Young SN, Missala K, Sourkes TL, Walsh J, et al. Narcolepsy and idiopthic hypersomnia: biogenic amines and related compounds in CSF. Neurology. 1982 Nov. 32 (11):1299-302. [QxMD MEDLINE Link].
Guilleminault C, Faull KF. Sleepiness in nonnarcoleptic, non-sleep apneic EDS patients: the idiopathic CNS hypersomnolence. Sleep. 1982. 5 Suppl 2:S175-81. [QxMD MEDLINE Link].
Petitjean F, Jouvet M. [Hypersomnia and increase of cerebral 5-hydroxyindoleacetic acid due to isthmic lesions in the cat]. C R Seances Soc Biol Fil. 1970. 164 (11):2288-93. [QxMD MEDLINE Link].
Kanbayashi T, Kodama T, Kondo H, Satoh S, Inoue Y, Chiba S, et al. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep. 2009 Feb 1. 32(2):181-7. [QxMD MEDLINE Link]. [Full Text].
Nishino S, Okuro M, Kotorii N, Anegawa E, Ishimaru Y, Matsumura M, et al. Hypocretin/orexin and narcolepsy: new basic and clinical insights. Acta Physiol (Oxf). 2009 Jun 25. [QxMD MEDLINE Link]. [Full Text].
Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev. 2005 Aug. 9(4):269-310. [QxMD MEDLINE Link].
Yamanaka A, Tsujino N, Funahashi H, Honda K, Guan JL, Wang QP, et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun. 2002. 290:1237-45. [QxMD MEDLINE Link]. [Full Text].
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Association;
Ohayon MM, Dauvilliers Y, Reynolds CF 3rd. Operational Definitions and Algorithms for Excessive Sleepiness in the General Population: Implications for DSM-5 Nosology. Arch Gen Psychiatry. 2012 Jan. 69(1):71-9. [QxMD MEDLINE Link].
Anderson KN, Pilsworth S, Sharples LD, Smith IE, Shneerson JM. Idiopathic hypersomnia: a study of 77 cases. Sleep. 2007 Oct. 30 (10):1274-81. [QxMD MEDLINE Link].
Vernet C, Arnulf I. Idiopathic hypersomnia with and without long sleep time: a controlled series of 75 patients. Sleep. 2009 Jun. 32 (6):753-9. [QxMD MEDLINE Link].
Bruck D, Parkes JD. A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data. J Neurol Neurosurg Psychiatry. 1996 May. 60 (5):576-8. [QxMD MEDLINE Link].
Broughton R et al. The socio-economic effects of idiopathic hypersomnia-comparison with controls and with compound narcoleptics. Sleep. 1978. 229-33.
Dauvilliers Y, Paquereau J, Bastuji H, Drouot X, Weil JS, Viot-Blanc V. Psychological health in central hypersomnias: the French Harmony study. J Neurol Neurosurg Psychiatry. 2009 Jun. 80 (6):636-41. [QxMD MEDLINE Link].
Vernet C, Leu-Semenescu S, Buzare MA, Arnulf I. Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness. J Sleep Res. 2010 Dec. 19 (4):525-34. [QxMD MEDLINE Link].
Bassetti C, Gugger M, Bischof M. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). Sleep Med. 2003 Jan. 4(1):7-12. [QxMD MEDLINE Link].
Ohayon MM. From wakefulness to excessive sleepiness: what we know and still need to know. Sleep Med Rev. 2008 Apr. 12(2):129-41. [QxMD MEDLINE Link].
Trotti LM, Saini P, Freeman AA, Bliwise DL, García PS, Jenkins A, et al. Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience. J Psychopharmacol. 2014 Jul. 28 (7):697-702. [QxMD MEDLINE Link].
Roehrs TA, Roth T. Chronic insufficient sleep and its recovery. Sleep Med. 2003 Jan. 4 (1):5-6. [QxMD MEDLINE Link].
Sangal RB, Sangal JM, Belisle C. Subjective and objective indices of sleepiness (ESS and MWT) are not equally useful in patients with sleep apnea. Clin Electroencephalogr. 1999 Apr. 30(2):73-5. [QxMD MEDLINE Link].
Rechtschaffen A, Roth B. Nocturnal sleep of hypersomniacs. Act Nerv Super (Praha). 1969. 11(3):229-33. [QxMD MEDLINE Link].
Sangal RB; Mitler MM; Sangal JM. Subjective sleepiness ratings (Epworth sleepiness scale) do not reflect the same parameter of sleepiness as objective sleepiness (maintenance of wakefulness test) in patients with narcolepsy. Clin Neurophysiol. Dec 1999. (110)12:2131-5. [QxMD MEDLINE Link].
Anderson KN, Pilsworth S, Sharples LD, Smith IE, Shneerson JM. Idiopathic hypersomnia: a study of 77 cases. Sleep. 2007 Oct 1. 30(10):1274-81. [QxMD MEDLINE Link].
Dement W, Rechtschaffen A, Gulevich G. The nature of the narcoleptic sleep attack. Neurology. 1966 Jan. 16(1):18-33. [QxMD MEDLINE Link].
Roth T. Introduction: narcolepsy and excessive daytime sleepiness: from the bench to the bedside. J Clin Psychiatry. 2007. 68 Suppl 13:4. [QxMD MEDLINE Link].
Schwartz JR. Modafinil: new indications for wake promotion. Expert Opin Pharmacother. 2005 Jan. 6(1):115-29. [QxMD MEDLINE Link].
[Guideline] Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007 Dec 1. 30(12):1705-11. [QxMD MEDLINE Link].
Xywav (calcium, magnesium, potassium, and sodium oxybates) [package insert]. Palo Alto, CA: Jazz Pharmaceuticals. August 2021. Available at [Full Text].
Ballon JS, Feifel D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006 Apr. 67(4):554-66. [QxMD MEDLINE Link].
Valentino RM, Foldvary-Schaefer N. Modafinil in the treatment of excessive daytime sleepiness. Cleve Clin J Med. 2007 Aug. 74(8):561-6, 568-71. [QxMD MEDLINE Link].
Poppe M, Friebel D, Reuner U, Todt H, Koch R, Heubner G. The Kleine-Levin syndrome - effects of treatment with lithium. Neuropediatrics. 2003. 34:113-9. [QxMD MEDLINE Link].
Roth B, Nevsimalova S, Rechtschaffen A. Hypersomnia with "sleep drunkenness". Arch Gen Psychiatry. 1972 May. 26(5):456-62. [QxMD MEDLINE Link].
Bassetti C, Pelayo R, Guilleminault C. Idiopathic Hypersomnia. Kryger MH, Roth T, Dement WC. Principles and Practices of Sleep Medicine. 4th Edition. Philadelphia, PA: Elsevier; 2005. 791-800.
Roth B, Nevsimalova S, Rechtschaffen A. Hypersomnia with "sleep drunkenness". Arch Gen Psychiatry. 1972 May. 26 (5):456-62. [QxMD MEDLINE Link].
Billiard M, Dauvilliers Y. Idiopathic Hypersomnia. Sleep Med Rev. 2001 Oct. 5 (5):349-358. [QxMD MEDLINE Link].
Bassetti C, Gugger M, Bischof M, Mathis J, Sturzenegger C, Werth E, et al. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). Sleep Med. 2003 Jan. 4 (1):7-12. [QxMD MEDLINE Link].
Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002 Oct. 59 (10):1553-62. [QxMD MEDLINE Link].
Dauvilliers Y, Baumann CR, Carlander B, Bischof M, Blatter T, Lecendreux M, et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry. 2003 Dec. 74 (12):1667-73. [QxMD MEDLINE Link].
Bové A, Culebras A, Moore JT, Westlake RE. Relationship between sleep spindles and hypersomnia. Sleep. 1994 Aug. 17 (5):449-55. [QxMD MEDLINE Link].
Baker TL, Guilleminault C, Nino-Murcia G, Dement WC. Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. Sleep. 1986. 9 (1 Pt 2):232-42. [QxMD MEDLINE Link].
Nicolas A, Lespérance P, Montplaisir J. Is excessive daytime sleepiness with periodic leg movements during sleep a specific diagnostic category?. Eur Neurol. 1998 Jul. 40 (1):22-6. [QxMD MEDLINE Link].
Montplaisir J, Fantini L. Idiopathic hypersomnia: a diagnostic dilemma. A commentary of "Idiopathic hypersomnia" (M. Billiard and Y. Dauvilliers). Sleep Med Rev. 2001 Oct. 5 (5):361-362. [QxMD MEDLINE Link].
Guilleminault C, Stoohs R, Clerk A, Cetel M, Maistros P. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest. 1993 Sep. 104 (3):781-7. [QxMD MEDLINE Link].
Roehrs T, Zorick F, Sicklesteel J, Wittig R, Roth T. Excessive daytime sleepiness associated with insufficient sleep. Sleep. 1983. 6 (4):319-25. [QxMD MEDLINE Link].

Media Gallery

Primary hypersomnia. Polysomnographic study demonstrates apnea (absence of carbon dioxide fluctuation indicating no flow), chest wall paradox, abrupt increase in tidal volume at the end of apnea, and oxygen desaturation. All of these features are consistent with obstructive sleep apnea.
Primary hypersomnia. In contrast to obstructive sleep apnea, mixed apnea shows absence of respiratory efforts in the first segment of the apnea.
Primary hypersomnia. Periodic limb movements show intermittent leg electromyogram activity accompanied by electroencephalogram arousals.

of 3

ISCD-3 Central Disorders of Hypersomnolence

ISCD-3 Central Disorders of Hypersomnolence

Primary

Secondary

Narcolepsy type 1 (NT1)

Narcolepsy type 2 (NT2)

Hypersomnia due to a medical condition

Hypersomnia due to a psychiatric condition

Idiopathic hypersomnia (IH)

Hypersomnia due to a drug or substance

Kleine-Levin syndrome (KLS)

Insufficient sleep syndrome (ISS)

Back to List

Author

Adrian Preda, MD Professor of Clinical Psychiatry and Human Behavior, University of California, Irvine, School of Medicine

Adrian Preda, MD is a member of the following medical societies: American Association for the Advancement of Science, American Psychiatric Association, International College of Neuropsychopharmacology, International Congress of Schizophrenia Research, Schizophrenia International Research Society, Society of Biological Psychiatry

Disclosure: Nothing to disclose.

Coauthor(s)

David R Bowman, MD Psychiatrist, Deputy Chief, Joint Behavioral Health Clinic, Multi-Disciplinary Outpatient Clinic, Medical Review Officer, Clinical Practice Guidelines Champion, External Behavioral Health Consultant, Department of Behavioral Health, Moncrief Army Health Clinic

David R Bowman, MD is a member of the following medical societies: American Psychiatric Association, American Society for Adolescent Psychiatry, American Society of Addiction Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Ana Hategan, MD, FRCPC Associate Clinical Professor, Department of Psychiatry and Behavioral Neurosciences, Division of Geriatric Psychiatry, McMaster University School of Medicine; Geriatric Psychiatrist, St Joseph's Health Care Hamilton, Canada

Ana Hategan, MD, FRCPC is a member of the following medical societies: Canadian Academy of Geriatric Psychiatry, Canadian Coalition for Seniors' Mental Health, Canadian Psychiatric Association, International Psychogeriatric Association, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada

Disclosure: Book royalties and/or honoraria for articles from American Psychiatric Publishing, Springer, and Current Psychiatry.

Acknowledgements

Jennifer S Morse, MD Associate Medical Director, Optum Health

Jennifer S Morse, MD is a member of the following medical societies: Academy of Psychosomatic Medicine, Aerospace Medical Association, and American Psychiatric Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Primary Hypersomnia Medication

Medication Summary

CNS Depressants

Class Summary

Calcium/magnesium/potassium/sodium oxybates (Xywav)

Calcium/magnesium/potassium/sodium oxybates (Xywav)

Stimulants